Alnylam Pharmaceuticals
Quarterly Financials
| Values in thousands | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 |
|---|---|---|---|---|
Revenue | $1,458,086 | $1,290,948 | $1,167,175 | $1,097,033 |
Gross Profit | 1,096,336 | 992,687 | 956,053 | 829,310 |
EBITDA | 394,658 | 245,067 | 304,492 | 303,979 |
EBIT | 380,182 | 231,168 | 290,939 | 290,473 |
Net Income | 2,167,335 | 164,494 | 205,991 | 186,419 |
Net Change In Cash | 1,458,086 | 1,290,948 | 1,167,175 | 1,097,033 |
Free Cash Flow | 271,153 | 40,642 | 48,671 | 140,263 |
Cash | 1,754,340 | 1,708,318 | 1,710,779 | 1,657,250 |
Basic Shares | 138,040 | 138,249 | 138,226 | 136,281 |
Annual Financials
| Values in thousands | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
Revenue | $3,713,937 | $2,248,243 | $1,828,292 | $1,037,418 |
Gross Profit | 3,036,771 | 1,924,873 | 1,517,886 | 868,601 |
EBITDA | 631,437 | -178,847 | -258,242 | -926,557 |
EBIT | 575,779 | -235,517 | -312,296 | -971,025 |
Net Income | 313,747 | -278,157 | -440,242 | -1,131,156 |
Net Change In Cash | 3,713,937 | 2,248,243 | 1,828,292 | 1,037,418 |
Cost of Revenue | 53,833 | |||
Free Cash Flow | 465,383 | -42,589 | 41,945 | -613,333 |
Cash | 1,657,250 | 966,428 | 812,688 | 866,394 |
Basic Shares | 134,684 | 127,651 | 124,906 | 121,689 |
Earnings Calls
| Quarter | EPS |
|---|---|
2026-09-30 | $15.72 |
2026-06-30 | $1.21 |
2026-03-31 | $1.99 |
2025-12-31 | $1.25 |